EXELIXIS Pipeline

Clinical trials and expected approvals

Pro Feature

Get full access to pipeline analysis, trial details, and approval forecasts.

-

Active Trials

-

Phase 3

-

Phase 2

-

Phase 1

-

Results Pending

📊

Pipeline Summary

FDA Decisions 2 upcoming PDUFA dates

Zanzalintinib (XL-092) + atezolizumab Pretreated metastatic colorectal cancer (mCRC) NDA

Dec 3, 2026 191 days Calendar →

zanzalintinib previously treated metastatic colorectal cancer NDA

Dec 3, 2026 191 days Calendar →

Loading...

Therapeutic Areas

Drug Targets

Companies

Explore

Indication mapping uses a manual taxonomy — see methodology and coverage there.